{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:24:41Z","timestamp":1759332281788,"version":"3.41.2"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00507","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T09:15:25Z","timestamp":1587460525000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer"],"prefix":"10.3389","volume":"10","author":[{"given":"Lingdi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baozhen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiepeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanli","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-Cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drup.2019.07.004","article-title":"Immune checkpoint inhibitor combinations: current efforts and important aspects for success","volume":"45","author":"Kon","year":"2019","journal-title":"Drug Resist Update"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","article-title":"Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma","volume":"10","author":"Khair","year":"2019","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","article-title":"MIncreased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer","volume":"13","author":"Park","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","article-title":"Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"112","author":"Schvartsman","year":"2017","journal-title":"Lung Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s40425-019-0637-6","article-title":"Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series","volume":"7","author":"Alsuwaigh","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1433981","DOI":"10.1080\/2162402X.2018.1433981","article-title":"PD-1\/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer","volume":"7","author":"Dosset","year":"2018","journal-title":"Oncoimmunology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: how cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8378","DOI":"10.1158\/0008-5472.CAN-07-0327","article-title":"Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells","volume":"67","author":"Tsuda","year":"2007","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1093\/carcin\/22.10.1727","article-title":"Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy","volume":"7","author":"Demaria","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"104258","DOI":"10.1016\/j.phrs.2019.104258","article-title":"Understanding and overcoming the resistance of cancer to PD-1\/PD-L1 blockade","volume":"145","author":"Shergold","year":"2019","journal-title":"Pharmacol Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00507\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T09:15:27Z","timestamp":1587460527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00507\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":21,"alternative-id":["10.3389\/fonc.2020.00507"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00507","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"article-number":"507"}}